• Policy
• HIRA starts preparing for RWE-based reimb reevaluations
• by Lee, Tak-Sun Nov 29, 2023 05:50am

• Policy
• DPM Choo ‘will finalize telemedicine plans this year'
• by Kang, Shin-Kook Nov 28, 2023 05:42am

• Company
• Korean companies bid to break AZ’s monopoly with FcRN drug
• by Son, Hyung-Min Nov 28, 2023 05:42am

• Company
• Budesonide’s price will be increased by up to 19%
• by Chon, Seung-Hyun Nov 28, 2023 05:41am

• Company
• Series of sales right transfers occur in KOR
• by Kim, Jin-Gu Nov 27, 2023 06:07am

• Company
• CDK4/6 inhibitor mkt fluctuates with the rise of Kisqali
• by Son, Hyung-Min Nov 27, 2023 06:06am

• Company
• New AD drug Adtralza enters last stage to reimb in KOR
• by Eo, Yun-Ho Nov 27, 2023 06:06am

• Company
• Sales of K-anticancer drugs Leclaz and Rolontis rise in KOR
• by Chon, Seung-Hyun Nov 24, 2023 05:37am

• Company
• MSD vaccines will be sold by Boryung·Kwangdong
• by Kim, Jin-Gu Nov 24, 2023 05:37am

• Company
• Reimb for 7 of 13 Keytruda indications to be rediscussed
• by Eo, Yun-Ho Nov 24, 2023 05:37am